Articles

Search Articles

Advanced search
Help

Catalogue

Articles

Databases

X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (140) 140
hematology (101) 101
index medicus (96) 96
leukemia, myelogenous, chronic, bcr-abl positive - drug therapy (87) 87
female (84) 84
male (80) 80
adult (76) 76
middle aged (76) 76
chronic myelogenous leukemia (74) 74
chronic myeloid leukemia (69) 69
aged (68) 68
imatinib mesylate (68) 68
hemic and lymphatic diseases (64) 64
treatment outcome (64) 64
oncology (62) 62
pyrimidines - therapeutic use (55) 55
imatinib (54) 54
antineoplastic agents - therapeutic use (53) 53
benzamides (52) 52
leukemia, myelogenous, chronic, bcr-abl positive - genetics (51) 51
protein kinase inhibitors - therapeutic use (47) 47
piperazines - therapeutic use (45) 45
adolescent (44) 44
aged, 80 and over (41) 41
fusion proteins, bcr-abl - genetics (37) 37
dasatinib (33) 33
nilotinib (30) 30
leukemia (29) 29
tyrosine kinase inhibitors (29) 29
young adult (29) 29
bcr-abl (27) 27
pyrimidines - administration & dosage (27) 27
chronic myeloid-leukemia (26) 26
therapy (25) 25
follow-up (24) 24
prognosis (24) 24
leukemia, myelogenous, chronic, bcr-abl positive - mortality (23) 23
abridged index medicus (21) 21
antineoplastic agents (21) 21
antineoplastic agents - adverse effects (21) 21
pyrimidines - adverse effects (21) 21
care and treatment (20) 20
disease-free survival (20) 20
follow-up studies (20) 20
piperazines - administration & dosage (19) 19
chronic-phase (18) 18
cml (18) 18
philadelphia chromosome (18) 18
survival rate (18) 18
antimitotic agents (17) 17
antineoplastic agents - administration & dosage (17) 17
hematology, oncology and palliative medicine (17) 17
leukemia, myelogenous, chronic, bcr-abl positive - diagnosis (17) 17
resistance (17) 17
survival (17) 17
time factors (17) 17
tyrosine (17) 17
analysis (16) 16
protein-tyrosine kinases - antagonists & inhibitors (16) 16
cancer (15) 15
leukemia, myeloid, chronic-phase - drug therapy (15) 15
protein kinase inhibitors - administration & dosage (15) 15
protein kinase inhibitors - adverse effects (15) 15
drug resistance, neoplasm (14) 14
interferon-alpha (14) 14
molecular response (14) 14
tyrosine kinase (14) 14
antineoplastic combined chemotherapy protocols - therapeutic use (13) 13
bone marrow transplantation (13) 13
leukemia, myelogenous, chronic, bcr-abl positive - therapy (13) 13
mesylate (13) 13
philadelphia-chromosome (13) 13
piperazines - adverse effects (13) 13
recommendations (13) 13
remission induction (13) 13
leukemia, myelogenous, chronic, bcr-abl positive - pathology (12) 12
neoplasms (12) 12
survival analysis (12) 12
thiazoles - therapeutic use (12) 12
chronic phase (11) 11
cytogenetic analysis (11) 11
cytogenetic responses (11) 11
drug resistance, neoplasm - genetics (11) 11
leukemia, myelogenous, chronic, bcr-abl positive - epidemiology (11) 11
management (11) 11
myeloid leukemia (11) 11
retrospective studies (11) 11
bcr-abl1 (10) 10
cell biology (10) 10
drug therapy (10) 10
european leukemianet (10) 10
genetic aspects (10) 10
minimal residual disease (10) 10
tyrosine kinase inhibitor (10) 10
acute lymphoblastic-leukemia (9) 9
benzamides - therapeutic use (9) 9
blast crisis (9) 9
breccia (9) 9
chronic granulocytic-leukemia (9) 9
clinical resistance (9) 9
more...
Language Language
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


1. Nilotinib: A viewpoint by Gianantonio Rosti
by Rosti, Gianantonio
Drugs, ISSN 0012-6667, 2008, Volume 68, Issue 4, pp. 460 - 460
Chronic myeloid leukaemia | Nilotinib, general | Adis Drug Profiles | Research and development | PHARMACOLOGY & PHARMACY | TOXICOLOGY | CHRONIC MYELOID-LEUKEMIA
Journal Article
Details down arrow
2. Full Text Nilotinib versus imatinib for the treatment of patients with newly diagnosed chronic phase, Philadelphia chromosome-positive, chronic myeloid leukaemia: 24-month minimum follow-up of the phase 3 randomised ENESTnd trial
by Kantarjian, Hagop M, Prof and Hochhaus, Andreas, Prof and Saglio, Giuseppe, Prof and De Souza, Carmino, Prof and Flinn, Ian W, MD and Stenke, Leif, MD and Goh, Yeow-Tee, MD and Rosti, Gianantonio, Prof and Nakamae, Hirohisa, MD and Gallagher, Neil J, MD and Hoenekopp, Albert, MD and Blakesley, Rick E, PhD and Larson, Richard A, Prof and Hughes, Timothy P, Prof
Lancet Oncology, The, ISSN 1470-2045, 2011, Volume 12, Issue 9, pp. 841 - 851
Summary Background Nilotinib has shown greater efficacy than imatinib in patients with newly diagnosed Philadelphia chromosome-positive chronic myeloid... 
Hematology, Oncology and Palliative Medicine | CHRONIC MYELOGENOUS LEUKEMIA | HALF | THERAPY | ONCOLOGY | MOLECULAR RESPONSES | RECOMMENDATIONS | HARMONIZING CURRENT METHODOLOGY | TYROSINE KINASE INHIBITOR | DISCONTINUATION | BCR-ABL TRANSCRIPTS | Piperazines - administration & dosage | Singapore | Protein-Tyrosine Kinases - metabolism | United States | Humans | Leukemia, Myelogenous, Chronic, BCR-ABL Positive - drug therapy | Leukemia, Myelogenous, Chronic, BCR-ABL Positive - genetics | Antineoplastic Agents - therapeutic use | Antineoplastic Agents - administration & dosage | Protein Kinase Inhibitors - adverse effects | Protein-Tyrosine Kinases - genetics | Time Factors | Antineoplastic Agents - adverse effects | Leukemia, Myelogenous, Chronic, BCR-ABL Positive - pathology | Brazil | Leukemia, Myelogenous, Chronic, BCR-ABL Positive - mortality | Philadelphia Chromosome | Leukemia, Myelogenous, Chronic, BCR-ABL Positive - enzymology | Drug Administration Schedule | Administration, Oral | Pyrimidines - administration & dosage | Europe | Kaplan-Meier Estimate | Survival Rate | Treatment Outcome | Piperazines - therapeutic use | Imatinib Mesylate | Piperazines - adverse effects | Disease-Free Survival | Protein Kinase Inhibitors - administration & dosage | Fusion Proteins, bcr-abl - genetics | Protein Kinase Inhibitors - therapeutic use | Pyrimidines - therapeutic use | Fusion Proteins, bcr-abl - antagonists & inhibitors | Pyrimidines - adverse effects | Benzamides | Australia | Fusion Proteins, bcr-abl - metabolism | Protein-Tyrosine Kinases - antagonists & inhibitors | Antimitotic agents | Antineoplastic agents | Product development
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
3. Full Text Tyrosine kinase inhibitors in chronic myeloid leukaemia: Which, when, for whom?
by Rosti, Gianantonio and Castagnetti, Fausto and Gugliotta, Gabriele and Baccarani, Michele
Nature Reviews Clinical Oncology, ISSN 1759-4774, 02/2017, Volume 14, Issue 3, pp. 141 - 154
The therapeutic armamentarium for chronic myeloid leukaemia (CML) comprises mainly tyrosine kinase inhibitors (TKIs), with several agents available for... 
CHRONIC MYELOGENOUS LEUKEMIA | TREATMENT-FREE REMISSION | EARLY MOLECULAR RESPONSE | PATIENTS TREATED FRONTLINE | EARLY CHRONIC PHASE | ONCOLOGY | PROGRESSION-FREE SURVIVAL | DURABLE CYTOGENETIC RESPONSES | PATIENTS RECEIVING IMATINIB | ARTERIAL OCCLUSIVE DISEASE | HIGH-DOSE IMATINIB | Pyrimidines - administration & dosage | Humans | Risk Factors | Leukemia, Myelogenous, Chronic, BCR-ABL Positive - drug therapy | Imidazoles - administration & dosage | Treatment Outcome | Clinical Trials as Topic | Fusion Proteins, bcr-abl - drug effects | Quinolines - administration & dosage | Remission Induction | Patient Selection | Nitriles - administration & dosage | Dasatinib - administration & dosage | Time Factors | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Protein Kinase Inhibitors - therapeutic use | Imatinib Mesylate - administration & dosage | Pyridazines - administration & dosage | Leukemia, Myelogenous, Chronic, BCR-ABL Positive - mortality | Aniline Compounds - administration & dosage | Protein-Tyrosine Kinases - antagonists & inhibitors | Tyrosine | Nonlymphoid leukemia | Dosage and administration | Myelocytic leukemia | Drug therapy
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
4. Full Text Ponatinib versus imatinib for newly diagnosed chronic myeloid leukaemia: an international, randomised, open-label, phase 3 trial
by Lipton, Jeffrey H, Prof and Chuah, Charles, MD and Guerci-Bresler, Agnès, MD and Rosti, Gianantonio, Prof and Simpson, David, Prof and Assouline, Sarit, MD and Etienne, Gabriel, MD and Nicolini, Franck E, MD and le Coutre, Philipp, Prof and Clark, Richard E, Prof and Stenke, Leif, MD and Andorsky, David, MD and Oehler, Vivian, MD and Lustgarten, Stephanie, PhD and Rivera, Victor M, PhD and Clackson, Timothy, PhD and Haluska, Frank G, MD and Baccarani, Michele, Prof and Cortes, Jorge E, Prof and Guilhot, François, Prof and Hochhaus, Andreas, Prof and Hughes, Timothy, Prof and Kantarjian, Hagop M, Prof and Shah, Neil P, Prof and Talpaz, Moshe, Prof and Deininger, Michael W, Prof and EPIC Investigators and EPIC investigators
Lancet Oncology, The, ISSN 1470-2045, 2016, Volume 17, Issue 5, pp. 612 - 621
Summary Background Ponatinib has shown potent activity against chronic myeloid leukaemia that is resistant to available treatment, although it is associated... 
Hematology, Oncology and Palliative Medicine | CHRONIC MYELOGENOUS LEUKEMIA | EARLY MOLECULAR RESPONSE | INTERFERON | ONCOLOGY | BOSUTINIB | RESISTANCE | TYROSINE KINASE INHIBITOR | FOLLOW-UP | DASATINIB | BCR-ABL1 TRANSCRIPT | NILOTINIB | Antineoplastic Combined Chemotherapy Protocols - administration & dosage | Humans | Middle Aged | Leukemia, Myelogenous, Chronic, BCR-ABL Positive - drug therapy | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Imidazoles - administration & dosage | Leukemia, Myelogenous, Chronic, BCR-ABL Positive - genetics | Male | Drug-Related Side Effects and Adverse Reactions - pathology | Imatinib Mesylate - adverse effects | Leukemia, Myelogenous, Chronic, BCR-ABL Positive - pathology | Imatinib Mesylate - administration & dosage | Pyridazines - administration & dosage | Aged, 80 and over | Adult | Female | Philadelphia Chromosome - drug effects | Pyridazines - adverse effects | Imidazoles - adverse effects | Kaplan-Meier Estimate | Treatment Outcome | Disease-Free Survival | Fusion Proteins, bcr-abl - genetics | Adolescent | Aged | Drug-Related Side Effects and Adverse Reactions - classification | Antimitotic agents | Clinical trials | Medical colleges | Product development | Research institutes | Antineoplastic agents | Analysis | Life Sciences | Cancer
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
5. Full Text Chronic myeloid leukemia: the concepts of resistance and persistence and the relationship with the BCR-ABL1 transcript type
by Baccarani, M and Rosti, G and Soverini, S
LEUKEMIA, ISSN 0887-6924, 10/2019, Volume 33, Issue 10, pp. 2358 - 2364
Chronic myeloid leukemia is driven by a hybrid gene, BCR-ABL1, that codes for a leukemogenic tyrosine kinase (TK) protein of 210 KDa (p210(BCR-ABL1))... 
BCR | TREATMENT-FREE REMISSION | CHRONIC-PHASE CML | EARLY MOLECULAR RESPONSE | DENDRITIC CELLS | ONCOLOGY | IMATINIB | ABL FUSION PROTEINS | E13A2 | HEMATOLOGY | CLINICAL-PRACTICE | EXPERT PANEL | Genetic aspects | Genetic transcription | Chronic myeloid leukemia | Drug therapy | Health aspects | Tyrosine | BCR protein | Therapy | GTP-binding protein | Immune response | Transcription | Myeloid leukemia | Leukemia | Abnormalities | Minimal residual disease | Amino acids | Kinases | Gene expression | Quality of life | Proteins | Remission | Protein-tyrosine kinase
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
6. Full Text A review of the European LeukemiaNet recommendations for the management of CML
by Baccarani, Michele and Castagnetti, Fausto and Gugliotta, Gabriele and Rosti, Gianantonio
Annals of Hematology, ISSN 0939-5555, 04/2015, Volume 94, Issue 2, pp. 141 - 147
Several guidelines and recommendations on the management of chronic myeloid leukemia (CML) have been prepared by several scientific societies. The European... 
Chronic myeloid leukemia | Tyrosine kinase inhibitors | BCR-ABL1 | Philadelphia chromosome | CHRONIC MYELOGENOUS LEUKEMIA | COMPLETE MOLECULAR REMISSION | BCR-ABL | CHRONIC MYELOID-LEUKEMIA | DIAGNOSED CHRONIC-PHASE | DASATINIB 100 MG | CHROMOSOME-POSITIVE LEUKEMIAS | PATIENTS RECEIVING IMATINIB | 3-YEAR FOLLOW-UP | HEMATOLOGY | Leukemia, Myelogenous, Chronic, BCR-ABL Positive - enzymology | Leukemia, Myelogenous, Chronic, BCR-ABL Positive - physiopathology | Drug Resistance, Multiple | Voluntary Health Agencies | Europe | Humans | Leukemia, Myelogenous, Chronic, BCR-ABL Positive - drug therapy | Leukemia, Myelogenous, Chronic, BCR-ABL Positive - genetics | Drug Resistance, Neoplasm | Antineoplastic Agents - therapeutic use | Protein Kinase Inhibitors - adverse effects | Evidence-Based Medicine | Disease Progression | Fusion Proteins, bcr-abl - genetics | Antineoplastic Agents - adverse effects | Protein Kinase Inhibitors - therapeutic use | Fusion Proteins, bcr-abl - antagonists & inhibitors | Mutation | Drug Monitoring | Fusion Proteins, bcr-abl - metabolism | Practice Guidelines as Topic | Analysis | Leukemia | Stem cells
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
7. Full Text Contribution of ABL Kinase Domain Mutations to Imatinib Resistance in Different Subsets of Philadelphia-Positive Patients: By the GIMEMA Working Party on Chronic Myeloid Leukemia
by Simona Soverini and Sabrina Colarossi and Alessandra Gnani and Gianantonio Rosti and Fausto Castagnetti and Angela Poerio and Ilaria Iacobucci and Marilina Amabile and Elisabetta Abruzzese and Ester Orlandi and Franca Radaelli and Fabrizio Ciccone and Mario Tiribelli and Roberto di Lorenzo and Clementina Caracciolo and Barbara Izzo and Fabrizio Pane and Giuseppe Saglio and Michele Baccarani and Giovanni Martinelli and GIMEMA Working Party Chronic Myelo and GIMEMA Working Party on Chronic Myeloid Leukemia and on behalf of the GIMEMA Working Party on Chronic Myeloid Leukemia
Clinical Cancer Research, ISSN 1078-0432, 12/2006, Volume 12, Issue 24, pp. 7374 - 7379
Purpose: ABL kinase domain mutations have been implicated in the resistance to the BCR-ABL inhibitor imatinib mesylate of Philadelphia-positive (Ph+) leukemia... 
Resistance | Imatinib | ABL mutations | CHRONIC MYELOGENOUS LEUKEMIA | CYTOGENETIC RESPONSES | POLYMERASE-CHAIN-REACTION | CHRONIC-PHASE | ONCOLOGY | RESIDUAL DISEASE DETECTION | TYROSINE KINASE | ACUTE LYMPHOBLASTIC-LEUKEMIA | BCR-ABL | BLAST CRISIS | CLINICAL RESISTANCE | Protein Kinases - genetics | Gene Frequency | Humans | Middle Aged | Leukemia, Myelogenous, Chronic, BCR-ABL Positive - drug therapy | Leukemia, Myelogenous, Chronic, BCR-ABL Positive - genetics | Antineoplastic Agents - therapeutic use | Piperazines - therapeutic use | Protein Structure, Tertiary - genetics | Chromatography, High Pressure Liquid | DNA Mutational Analysis - methods | Imatinib Mesylate | Mutation - physiology | Drug Resistance, Neoplasm - genetics | Pyrimidines - therapeutic use | Leukemia, Myelogenous, Chronic, BCR-ABL Positive - pathology | Adolescent | Adult | Aged | Benzamides | Neoplasm Staging | Genes, abl - physiology
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
8. Full Text Dasatinib in the Treatment of Chronic Myeloid Leukemia in Accelerated Phase After Imatinib Failure: The START A Trial
by Jane F. Apperley and Jorge E. Cortes and Dong-Wook Kim and Lydia Roy and Gail J. Roboz and Gianantonio Rosti and Eduardo O. Bullorsky and Elisabetta Abruzzese and Andreas Hochhaus and Dominik Heim and Carmino A. de Souza and Richard A. Larson and Jeffrey H. Lipton and H. Jean Khoury and Hyeoung-Joon Kim and Christian Sillaber and Timothy P. Hughes and Philipp Erben and Jan Van Tornout and Richard M. Stone
Journal of Clinical Oncology, ISSN 0732-183X, 07/2009, Volume 27, Issue 21, pp. 3472 - 3479
Purpose Patients with chronic myelogenous leukemia in accelerated phase (CML-AP) that is resistant or intolerant to imatinib have limited therapeutic options.... 
CHRONIC MYELOGENOUS LEUKEMIA | CYTOGENETIC RESPONSES | LYN | THERAPY | INDEPENDENCE | ONCOLOGY | BCR-ABL | BLAST CRISIS | RESISTANCE | FOLLOW-UP | STEM-CELL TRANSPLANTATION | Dasatinib | Humans | Middle Aged | Leukemia, Myelogenous, Chronic, BCR-ABL Positive - drug therapy | Male | Treatment Outcome | Piperazines - therapeutic use | Thiazoles - therapeutic use | Imatinib Mesylate | Young Adult | Disease-Free Survival | Precursor Cell Lymphoblastic Leukemia-Lymphoma - drug therapy | Pyrimidines - therapeutic use | Treatment Failure | Aged, 80 and over | Adult | Female | Aged | Benzamides | ORIGINAL REPORTS | Hema5
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
9. Full Text ABL Mutations in Late Chronic Phase Chronic Myeloid Leukemia Patients With Up-Front Cytogenetic Resistance to Imatinib Are Associated With a Greater Likelihood of Progression to Blast Crisis and Shorter Survival: A Study by the GIMEMA Working Party on Chronic Myeloid Leukemia
by Simona Soverini and Giovanni Martinelli and Gianantonio Rosti and Simona Bassi and Marilina Amabile and Angela Poerio and Barbara Giannini and Elena Trabacchi and Fausto Castagnetti and Nicoletta Testoni and Simona Luatti and Antonio de Vivo and Daniela Cilloni and Barbara Izzo and Milena Fava and Elisabetta Abruzzese and Daniele Alberti and Fabrizio Pane and Giuseppe Saglio and Michele Baccarani
Journal of Clinical Oncology, ISSN 0732-183X, 06/2005, Volume 23, Issue 18, pp. 4100 - 4109
Purpose Point mutations within the ABL kinase domain of the BCR-ABL gene have been associated with clinical resistance to imatinib mesylate in chronic myeloid... 
PERFORMANCE LIQUID-CHROMATOGRAPHY | CHRONIC MYELOGENOUS LEUKEMIA | KINASE INHIBITOR BMS-354825 | POSITIVE CELLS | ONCOLOGY | TYROSINE KINASE | ACUTE LYMPHOBLASTIC-LEUKEMIA | BCR-ABL | CLINICAL RESISTANCE | DOMAIN MUTATIONS | I DOSE-ESCALATION | Prognosis | Genes, abl - genetics | Humans | Middle Aged | Male | Antineoplastic Agents - therapeutic use | Chromatography, High Pressure Liquid | DNA Mutational Analysis | Statistics, Nonparametric | Adult | Female | Blast Crisis | Leukemia, Myeloid, Chronic-Phase - drug therapy | Cytogenetic Analysis - methods | Piperazines - therapeutic use | Chi-Square Distribution | Reverse Transcriptase Polymerase Chain Reaction | Imatinib Mesylate | Disease Progression | Point Mutation | Drug Resistance, Neoplasm - genetics | Pyrimidines - therapeutic use | Survival Analysis | Aged | Benzamides | Leukemia, Myeloid, Chronic-Phase - genetics
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
10. Full Text Predicting complete cytogenetic response and subsequent progression-free survival in 2060 patients with CML on imatinib treatment: the EUTOS score
by Hasford, J and Baccarani, M and Hoffmann, V and Guilhot, J and Saussele, S and Rosti, G and Guilhot, F and Porkka, K and Ossenkoppele, G.J and Lindoerfer, D and Simonsson, B and Pfirrmann, M and Hehlmann, R and Medicinska fakulteten and Medicinska och farmaceutiska vetenskapsområdet and Uppsala universitet and Institutionen för medicinska vetenskaper and Medicin
Blood, ISSN 0006-4971, 2011, Volume 118, Issue 3, pp. 686 - 692
The outcome of chronic myeloid leukemia (CML) has been profoundly changed by the introduction of tyrosine kinase inhibitors into therapy, but the prognosis of... 
CHRONIC MYELOGENOUS LEUKEMIA | CELLS | CHRONIC GRANULOCYTIC-LEUKEMIA | PHASE | THERAPY | MOLECULAR RESPONSES | RISK | SPLENECTOMY | COMBINATION | HEMATOLOGY | CHRONIC MYELOID-LEUKEMIA | Piperazines - administration & dosage | Predictive Value of Tests | Risk Assessment - methods | Prognosis | Humans | Middle Aged | Leukemia, Myelogenous, Chronic, BCR-ABL Positive - drug therapy | Leukemia, Myelogenous, Chronic, BCR-ABL Positive - genetics | Male | Antineoplastic Agents - administration & dosage | Young Adult | Basophils - pathology | Registries - statistics & numerical data | Aged, 80 and over | Adult | Female | Spleen - pathology | Leukemia, Myelogenous, Chronic, BCR-ABL Positive - mortality | Pyrimidines - administration & dosage | Risk Factors | Models, Statistical | Imatinib Mesylate | Disease Progression | Disease-Free Survival | Adolescent | Aged | Benzamides | Medical and Health Sciences | MEDICINE | Medicin och hälsovetenskap | MEDICIN
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
11. Full Text BCR-ABL kinase domain mutation analysis in chronic myeloid leukemia patients treated with tyrosine kinase inhibitors: Recommendations from an expert panel on behalf of European LeukemiaNet
by Soverini, Simona and Hochhaus, Andreas and Nicolini, Franck E and Gruber, Franz and Lange, Thoralf and Saglio, Giuseppe and Pane, Fabrizio and Müller, Martin C and Ernst, Thomas and Rosti, Gianantonio and Porkka, Kimmo and Baccarani, Michele and Cross, Nicholas C.P and Martinelli, Giovanni
Blood, ISSN 0006-4971, 08/2011, Volume 118, Issue 5, pp. 1208 - 1215
Mutations in the Bcr-Abl kinase domain may cause, or contribute to, resistance to tyrosine kinase inhibitors (TKIs) in chronic myeloid leukemia patients.... 
CHRONIC MYELOGENOUS LEUKEMIA | CYTOGENETIC RESPONSES | PHILADELPHIA-POSITIVE PATIENTS | ACUTE LYMPHOBLASTIC-LEUKEMIA | CLINICAL RESISTANCE | NILOTINIB FORMERLY AMN107 | IMATINIB DOSE-ESCALATION | LATE CHRONIC PHASE | HEMATOLOGY | IN-VITRO ACTIVITY | GIMEMA WORKING PARTY | Fusion Proteins, bcr-abl - chemistry | Europe | Humans | Societies, Medical - legislation & jurisprudence | Leukemia, Myelogenous, Chronic, BCR-ABL Positive - drug therapy | Leukemia, Myelogenous, Chronic, BCR-ABL Positive - genetics | Protein Structure, Tertiary - genetics | Societies, Medical - organization & administration | Community Networks | Fusion Proteins, bcr-abl - genetics | Protein Kinase Inhibitors - therapeutic use | Mutation | Expert Testimony | Phosphotransferases - genetics | Practice Guidelines as Topic
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
12. Full Text European LeukemiaNet recommendations for the management of chronic myeloid leukemia: 2013
by Baccarani, Michele and Deininger, Michael W and Rosti, Gianantonio and Hochhaus, Andreas and Soverini, Simona and Apperley, Jane F and Cervantes, Francisco and Clark, Richard E and Cortes, Jorge E and Guilhot, François and Hjorth-Hansen, Henrik and Hughes, Timothy P and Kantarjian, Hagop M and Kim, Dong-Wook and Larson, Richard A and Lipton, Jeffrey H and Mahon, François-Xavier and Martinelli, Giovanni and Mayer, Jiri and Müller, Martin C and Niederwieser, Dietger and Pane, Fabrizio and Radich, Jerald P and Rousselot, Philippe and Saglio, Giuseppe and Saußele, Susanne and Schiffer, Charles and Silver, Richard and Simonsson, Bengt and Steegmann, Juan-Luis and Goldman, John M and Hehlmann, Rüdiger and Medicinska fakulteten and Medicinska och farmaceutiska vetenskapsområdet and Uppsala universitet and Institutionen för medicinska vetenskaper and Hematologi
Blood, ISSN 0006-4971, 08/2013, Volume 122, Issue 6, pp. 872 - 884
Advances in chronic myeloid leukemia treatment, particularly regarding tyrosine kinase inhibitors, mandate regular updating of concepts and management. A... 
TYROSINE KINASE INHIBITORS | CHRONIC MYELOGENOUS LEUKEMIA | SUBCUTANEOUS OMACETAXINE MEPESUCCINATE | BCR-ABL1 TRANSCRIPT LEVELS | DIAGNOSED CHRONIC-PHASE | COMPLETE MOLECULAR REMISSION | MAJOR CYTOGENETIC RESPONSE | PATIENTS RECEIVING IMATINIB | ARTERIAL OCCLUSIVE DISEASE | STEM-CELL TRANSPLANTATION | HEMATOLOGY | Dasatinib | Prognosis | Europe | Humans | Leukemia, Myelogenous, Chronic, BCR-ABL Positive - drug therapy | Treatment Outcome | Antineoplastic Agents - therapeutic use | Leukemia, Myelogenous, Chronic, BCR-ABL Positive - therapy | Piperazines - therapeutic use | Thiazoles - therapeutic use | Imatinib Mesylate | Randomized Controlled Trials as Topic | Stem Cell Transplantation | Benzamides - therapeutic use | Pyrimidines - therapeutic use | Fusion Proteins, bcr-abl - metabolism | Review | Medical and Health Sciences | Medicin och hälsovetenskap
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights